Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP-2509 engages the endoplasmic reticulum stress response.

Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S, Lessnick SL.

Mol Cancer Ther. 2018 Jul 11. pii: molcanther.0373.2018. doi: 10.1158/1535-7163.MCT-18-0373. [Epub ahead of print]

PMID:
29997151
2.

Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.

Shakya R, Tarulli GA, Sheng L, Lokman NA, Ricciardelli C, Pishas KI, Selinger CI, Kohonen-Corish MRJ, Cooper WA, Turner AG, Neilsen PM, Callen DF.

Oncogene. 2017 Aug;36(31):4469-4480. doi: 10.1038/onc.2017.66. Epub 2017 Apr 3.

PMID:
28368395
3.

Recent advances in targeted therapy for Ewing sarcoma.

Pishas KI, Lessnick SL.

F1000Res. 2016 Aug 25;5. pii: F1000 Faculty Rev-2077. doi: 10.12688/f1000research.8631.1. eCollection 2016. Review.

4.

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.

Theisen ER, Pishas KI, Saund RS, Lessnick SL.

Oncotarget. 2016 Apr 5;7(14):17616-30. doi: 10.18632/oncotarget.7124. Review.

5.

Identification of vitamin D3 target genes in human breast cancer tissue.

Sheng L, Anderson PH, Turner AG, Pishas KI, Dhatrak DJ, Gill PG, Morris HA, Callen DF.

J Steroid Biochem Mol Biol. 2016 Nov;164:90-97. doi: 10.1016/j.jsbmb.2015.10.012. Epub 2015 Oct 17.

PMID:
26485663
6.

Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH, Callen DF.

Sci Rep. 2015 Aug 27;5:13328. doi: 10.1038/srep13328. No abstract available.

7.

XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH, Callen DF.

Sci Rep. 2015 Jun 22;5:11465. doi: 10.1038/srep11465. Erratum in: Sci Rep. 2015;5:13328.

8.

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.

Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW, Lawrence DM, Perugini M, Whitfield RJ, Farshid G, Manavis J, Chryssidis S, Mayo BJ, Haycox RC, Ho K, Brown MP, D'Andrea RJ, Evdokiou A, Thomas DM, Desai J, Callen DF, Neilsen PM.

Cancer Res. 2014 Feb 1;74(3):921-31. doi: 10.1158/0008-5472.CAN-13-2424. Epub 2013 Dec 13.

9.

Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy.

Pishas KI, Neuhaus SJ, Clayer MT, Adwal A, Brown MP, Evdokiou A, Callen DF, Neilsen PM.

Oncol Rep. 2013 Jul;30(1):471-7. doi: 10.3892/or.2013.2454. Epub 2013 May 13.

PMID:
23670273
10.

New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.

Neilsen PM, Pehere AD, Pishas KI, Callen DF, Abell AD.

ACS Chem Biol. 2013 Feb 15;8(2):353-9. doi: 10.1021/cb300549d. Epub 2012 Nov 28.

PMID:
23190346
11.

A comparison of vitamin D activity in paired non-malignant and malignant human breast tissues.

Suetani RJ, Ho K, Jindal S, Manavis J, Neilsen PM, Pishas KI, Rippy E, Bochner M, Kollias J, Gill PG, Morris HA, Callen DF.

Mol Cell Endocrinol. 2012 Oct 15;362(1-2):202-10. doi: 10.1016/j.mce.2012.06.022. Epub 2012 Jun 29.

PMID:
22750718
12.

Targeting the p53 Pathway in Ewing Sarcoma.

Neilsen PM, Pishas KI, Callen DF, Thomas DM.

Sarcoma. 2011;2011:746939. doi: 10.1155/2011/746939. Epub 2010 Dec 9.

13.

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM.

Clin Cancer Res. 2011 Feb 1;17(3):494-504. doi: 10.1158/1078-0432.CCR-10-1587. Epub 2010 Nov 23.

Supplemental Content

Loading ...
Support Center